SOTERIA and Tempus Partner to Enhance Cancer Care for Veterans
Collaboration aims to provide advanced oncology insights for military personnel.
SOTERIA Precision Medicine Foundation has announced a partnership with Tempus to enhance precision oncology for U.S. military members and veterans facing cancer. This collaboration focuses on delivering personalized cancer treatment insights and advanced genomic sequencing through SOTERIA's Cancer Hunt initiative.
The partnership will use Tempus' genomic profiling and AI-driven diagnostic capabilities to identify targeted therapies and clinical trial opportunities. This is particularly relevant as military personnel are increasingly diagnosed with cancer at younger ages and often at more advanced stages.
SOTERIA aims to bridge a critical care gap by providing patient-centric navigation in precision oncology. The organization will help CLIA-validated germline and somatic sequencing, ensuring that treatment decisions are informed by thorough molecular data.
Julia Civardi, Founder and CEO of SOTERIA, emphasized the importance of this collaboration, stating, "Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them." The integration of Tempus’ capabilities is expected to provide clearer, actionable treatment options for both patients and healthcare teams.
Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus, noted that the collaboration allows for the delivery of latest genomic insights to clinicians and patients at critical decision points. This initiative aims to advance precision oncology specifically tailored for the military community.
As part of the effort, SOTERIA will simplify molecular profiling and data integration for its patient cohort, improving oncology research and optimizing care pathways. This partnership represents a significant step towards addressing the unique healthcare challenges faced by service members and veterans diagnosed with cancer.
The announcement was distributed via PR Newswire.
This is an independent summary of a press release originally distributed via PR Newswire. GAX Online was not paid for this coverage.
Have news to announce?
Get your launch, funding round, or partnership covered on GAX Online, in front of tech buyers and the AI answer engines that cite us.
Submit your press release →